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 ABSTRACT 
 
The human uterine cervix is capable of 
producing nitric oxide (NO), a free radical 
gas with an ultra-short half-life. We 
studied cervical NO release by measuring 
the levels of NO metabolites (Nox) in 
cervical fluid in 664 nonpregnant and 
pregnant women. In addition, the 
expression of inducible and endothelial 
NO synthases was studied in cervical 
tissue. 
 
Cervical fluid Nox was more often 
detectable and higher in concentration in 
the follicular phase (93%, median 18.6 
µmol/l) than in the luteal phase (46%, 
median < 3.8 µmol/l). Cervical fluid Nox 
was more often detectable and higher in 
concentration in cases of blighted ovum 
(87%, median 25.6 µmol/l) and in missed 
abortion (90%, median 59.4 µmol/l) than 
in normal early pregnancy (55 to 68%, 
median 4.3 to 11.4 µmol/l); Nox levels in 
women with tubal pregnancy were not 
elevated. The lower the circulating 
progesterone level, the higher the cervical 
NO release in nonviable pregnancy. 
Cervical NO release was reduced in 
postterm pregnancy. Postterm women 
with low cervical NO failed more often to 
progress in labor and had longer duration 
of labor than postterm women with high 
NO release. 
 
The riper the cervix, the higher was the 
cervical NO release. Parous women had 
higher cervical fluid Nox than nulliparous 
women. Cervical NO release was induced 
by spontaneous uterine contractions (3.5-
fold), and by cervical manipulation (6.6-
fold). 
 
The prostaglandin (PG) E1 analogue 
misoprostol administrated vaginally 
induced in three hours a 5.2-fold 
elevation in cervical NO in early 
pregnancy and an 18.2-fold elevation in 
late pregnancy, but had no effect in 
nonpregnant women. The antiprogestin 
mifepristone induced in three hours a 
17.2-fold elevation in cervical NO in early 
viable pregnancy. 
 
The expression of both iNOS and eNOS 
was detected by immunohistochemistry 
and Western blotting in the cervical cells: 
both of them in the vascular endothelium, 
iNOS in pericytes and fibroblasts, and 
eNOS in the parabasal cells of the 
surface epithelium and the cervical 
glandular epithelial cells. The expression 
of iNOS was stimulated by mifepristone 
and, additionally, the presence of iNOS 
was seen in the cervical glands. 
 
Cervical NO release became stimulated 
during both physiological and 
pharmacologically induced cervical 
ripening in pregnant women. Increased 
preabortal cervical nitric oxide release in 
women with nonviable pregnancy may 
contribute to onset of clinical abortion. 
Reduced cervical NO release may 
contribute to postterm pregnancy. 
Prostaglandin-induced cervical NO 
release suggests a joint action of NO and 
PGs in cervical ripening. Mifepristone-
induced release of NO and elevated 
expression of iNOS implies that 
mifepristone may initiate cervical ripening 
by the NO pathway. 
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INTRODUCTION 
 
he discovery of an endothelium-
derived relaxing factor (Furchgott 
and Zawadzki 1980), and its later 
identification as nitric oxide (NO) (Ignarro 
et al 1987) have to be considered as 
among the most exciting discoveries in 
medicine in the 1980s. Therefore, it was 
no surprise that NO was nominated 
Science’s “molecule of the year” in 1992, 
and its discovery was rewarded with the 
Nobel Prize in 1998. Nitric oxide is a 
small uncharged gas molecule that is a 
highly reactive free radical with an 
extremely short half-life of approximately 
four seconds. It has been shown to be a 
major paracrine mediator of numerous 
biological processes, including smooth 
muscle relaxation, host defense and 
inflammation (Ignarro et al. 1987, 
Moncada and Higgs 1993, Alderton et al. 
2001, Korhonen et al. 2005). In fact, NO 
is involved in almost all areas of biology 
and medicine. 
 
The uterine cervix has a pivotal role in the 
physiology of gestation and parturition; it 
has to be firm enough to retain the 
conceptus throughout pregnancy and, on 
the other hand, have the ability to soften 
before and during labor to enable the 
birth of the infant. Cervical ripening is 
actively controlled and shows features 
similar to those in inflammation in 
rearrangement of the cervical collagen 
fibers (Denison et al. 1999, Sennström et 
al. 2000). Cervical ripening is thus 
associated with changes in local 
cytokines, prostaglandins, and 
metalloproteases, as well as in other 
bioregulators that play roles in 
inflammation and in collagen metabolism 
(Denison et al. 1999, Sennström et al. 
2000). These factors also take part in the 
regulation of NO synthesis and release 
(Maul et al. 2003a), and indeed, animal 
data have suggested that NO is a factor 
in cervical ripening (Chwalisz and 
Garfield 1997, Chwalisz et al. 1997, 
Chwalisz and Garfield 1998, Chwalisz et 
al. 1999). Therefore, the possibility 
existed that cervical NO also plays a role 
in ripening of the human uterine cervix. 
The present study was designed to clarify 
this question. 
T 
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REVIEW OF THE LITERATURE 
1. NITRIC OXIDE 
Nitric oxide is a gaseous, colorless, highly 
reactive short-lived molecule which 
regulates various physiological and 
pathophysiological conditions in the body 
(Änggård 1994, Aktan 2004). It is formed 
in almost all cell types. Despite its 
extremely short half-life in vivo of 
approximately four seconds, it penetrates 
the surrounding tissues and activates a 
variety of cellular signaling pathways 
(Henry et al. 1993). It is soluble both in 
water and lipids (Henry et al. 1993). 
1.1 Synthesis 
Nitric oxide is formed from L-arginine 
(Palmer et al. 1988) through nitric oxide 
synthases (NOS) (Palmer and Moncada 
1989), a group of enzymes that 
structurally resemble cytochrome P-450 
reductase (Marletta 1994). The 
biosynthesis of NO takes place from L-
arginine and molecular oxygen, utilizing 
nicotinamide adenine dinucleotide 
phosphate as an electron donor and 
heme, tetrahydrobiopterin, calmodulin, 
and flavin adenine mono- and 
dinucleotides as cofactors through a 
reaction that consumes five electrons 
(Figure 1). The overall reaction consists 
of a two-step oxidative conversion of L-
arginine to NO and L-citrulline via Nw-
hydroxy-L-arginine as an intermediate, 
with monooxygenase I and 
monooxygenase II, in each step a mixed-
function oxidation taking place (Aktan 
2004) (Figure 1). 
 
Three NOS isoenzymes have been 
characterized as neuronal NOS (type I, 
nNOS, also called bNOS), inducible NOS 
(type II or iNOS), and endothelial NOS 
(type III or eNOS) (Pollock et al. 1991, 
Xie et al. 1992, Nakane et al. 1993). Their 
syntheses are regulated by genes located 
in chromosomes 12, 17 and 7, 
respectively (Mayer and Hemmens 1997). 
The amino acid identity between different 
human NOS isoforms is approximately 
55% (Michel and Feron 1997). Both 
nNOS and eNOS are expressed 
constitutively, and their activity is 
calcium/calmodulin-dependent, whereas 
the expression of iNOS is induced by 
bacterial lipopolysaccharides (LPS) and 
cytokines, independently of calcium 
(Knowles and Moncada 1994) (Table 1). 
 
 
Figure 1: The synthesis of nitric oxide (NO) from L-arginine. Nitric oxide is synthesized by the 
conversion of L-arginine to L-citrulline. During this reaction, NADPH (1.5 molecules) is used as an 
electron donor and hydroxyl-arginine is generated as an intermediate. 
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Table 1: Comparison of the constitutive and inducible nitric oxide synthases. 
 
Nitric oxide synthase 
 
 
Neuronal 
 
Inducible 
 
Endothelial 
 
 
Molecular mass (kDa) 
 
160 
 
130 
 
140 
Examples of  
• cellular sources 
 
neurons 
 
macrophages 
smooth muscle cells 
 
endothelial cells 
• target organs nerves microbes vascular smooth muscle
Expression constitutive inducible constitutive 
Activity regulation Ca-calmodulin transcriptional increased Ca-calmodulin 
Amount of NO 
release  
10-12  
(pmol) 
10 -9 
(nmol) 
10-12 
(pmol) 
 
Activators and 
inducers 
 
sex hormones 
cytokines 
stress  
physical exercise 
 
inflammatory mediators 
cytokines 
kinases 
LPS  
PG  
 
acetylcholine 
bradykinin 
sex hormones 
mechanical pressure 
physical exercise 
 
LPS, lipopolysaccharide; PG, prostaglandin 
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 Endothelial NOS is mainly expressed in 
endothelial cells (Pollock et al. 1991) and 
platelets (Radomski et al. 1990), while 
nNOS is expressed in the cerebellum and 
skeletal muscle (Nakane et al. 1993). 
Inducible NOS was first cloned from 
activated mouse macrophages (Xie et al. 
1992), and thereafter it has been 
demonstrated in various human cells 
including macrophages (Moilanen et al. 
1997, Aktan 2004) (Table 1). 
1.2 As a mediator 
Nitric oxide serves as a highly diffusible 
first messenger that can affect cells both 
directly and indirectly. The direct effects 
are mediated by the NO molecule itself, 
while the indirect ones are mediated by 
reactive nitrogen produced by the 
interaction of NO with oxygen or 
superoxide radicals (O2-). At the low 
concentrations of NO produced through 
eNOS and nNOS, the direct effects 
prevail, while at higher concentrations of 
NO, produced through iNOS, the indirect 
effects dominate (Murad 1999, Davis et 
al. 2001) (Table 1). 
 
The formation of cyclic guanosine 3’,5’-
monophosphate (cGMP) accounts for 
many of the direct physiological effects of 
NO (Ignarro et al. 1999, Murad 1999). 
Nitric oxide may also interact with 
nonheme iron-containing and zinc-
containing proteins, or form S-
nitrosothiols by nitrosylation (Davis et al. 
2001, Hogg 2002). 
 
The indirect effects of NO include 
oxidation, nitrosation and nitration (Davis 
et al. 2001). Cytokine-induced NO 
production mediates cytotoxicity in the 
target cells of macrophages (Farrell and 
Blake 1996). In a reaction with O2 (auto-
oxidation) NO forms dinitrogen trioxide 
(N2O3), which can mediate DNA 
deamination and nitrosylation. By reacting 
with superoxide NO produces 
peroxynitrite (ONOO-), which is a toxic 
nitrating agent and a powerful oxidant, 
modifying proteins, lipids, tyrosine and 
nucleic acids (Davis et al. 2001). 
1.3 Assessment 
The detection of endogenous NO in 
biological systems is challenging because 
of its very short half-life. Nitric oxide was 
first quantified by means of 
chemiluminescence assay, since its 
interaction with ozone produces light 
(Palmer et al. 1987). In vitro, NO-specific 
microelectrodes have been used for the 
detection of NO (Tsukahara et al. 1993). 
Furthermore, a rapid-response chemi-
luminescence analyzer has been used for 
the detection of NO (Lee et al. 2000). 
Measurement of the conversion of radio-
labeled arginine to citrulline can be used 
to measure NO production, as well as the 
formation of its second messenger cGMP 
(Ogden and Moore 1995). Unfortunately, 
this method may give false negative 
results because hemoglobin catches NO 
before its reaction with guanylate cyclase. 
The production of NO can also be 
detected by positive NADPH diaphorase 
activity (Rosselli et al. 1996, Ekerhövd et 
al. 1997). 
 
The assessment of NO in vivo is even 
more difficult. Endothelial vasomotor 
function, reflecting NO release in vivo, 
can be measured by forearm venous 
occlusion plethysmography and by pulse-
wave analysis. In plethysmography 
endothelium-dependent vasodilatation is 
measured as the increase in blood flow in 
response to intra-arterial administration of 
drugs such as acetylcholine that increase 
NO production (Benjamin et al. 1995). In 
pulse-wave analysis the shape of the 
arterial pressure waveform reflecting 
arterial stiffness is measured (Wilkinson 
et al. 2002). The expression of NOSs 
responsible for NO production has been 
assessed in various tissues by Western 
blotting and immunohistochemistry 
(Tschugguel et al. 1999, Alderton et al. 
2001, Kakui et al. 2004, Aktan 2004, 
Törnblom et al. 2005), and the results 
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have been related to NO release. 
However, the collection of tissue biopsy 
samples in vivo can be considered 
unethical and it certainly causes trauma, 
which may artificially modify the release 
of NO. 
 
Nitric oxide is rapidly converted to stable 
NO metabolites, nitrate and nitrite (Nox) 
which can be assayed both in vitro and in 
vivo by means of the Griess reaction in 
physiological fluids, e.g. plasma, urine, 
peritoneal and follicular fluid (Green et al. 
1982, Orpana et al. 1996, Dong et al. 
2001, Osborn et al. 2002). Vaginal fluid 
has also been assayed for Nox 
(Nakatsuka et al. 2000). Griess reagent 
forms azo dye with nitrite, which can be 
spectrophotometrically measured (Green 
et al. 1982). Nitrate in the sample must be 
reduced to nitrite before the assay (Green 
et al. 1982), and plasma samples need to 
be deproteinized (Moshage et al. 1995). 
Food rich in nitrate (such as red meat, 
many vegetables, teas, malt beverages 
and wine) elevate plasma nitrate levels. 
Therefore, oral intake of Nox-rich food 
should be restricted for 48 h before taking 
samples for plasma Nox assay 
(Jungersten et al. 1996). 
 
No method for measurement of Nox in 
cervical fluid existed when the present 
study was designed. 
1.4 General effects 
Nitric oxide is an important intra- and 
intercellular signaling molecule involved 
in the regulation of diverse physiological 
and pathophysiological mechanisms in 
cardiovascular, nervous and 
immunological systems (Moncada and 
Higgs 1993, Alderton et al. 2001, Aktan 
2004, Korhonen et al. 2005). It relaxes 
vascular smooth muscles, inhibits platelet 
aggregation, stimulates angiogenesis, 
reduces blood pressure and transmits 
neuronal signals. It also activates 
macrophages to synthesize large 
amounts of microorganism-destroying 
NO, mainly through iNOS (Ignarro et al. 
1987, Moncada and Higgs 1993, Alderton 
et al. 2001, Aktan 2004). On the other 
hand, it can act as a cytotoxic agent in 
inflammatory disorders (Moncada and 
Higgs 1993, Alderton et al. 2001, Aktan 
2004, Korhonen et al. 2005). Nitric oxide 
may also play a role in asthma (Korhonen 
et al. 2005) and interestingly, patients 
with asthmatic symptoms but normal lung 
function have also been shown to have 
increased alveolar and bronchial NO 
concentrations (Lehtimäki et al 2005). In 
summary, nitric oxide is involved on a 
very large scale in human physiology. 
1.5 In reproduction 
Nitric oxide takes part in various functions 
of female and male reproduction (Rosselli 
et al. 1998) (Figure 2). In the reproductive 
system NO was first recognized to have a 
role in male penile erection (Ignarro et al. 
1990), and nowadays it is known to play a 
key role in the physiology of erection as 
well as in sperm motility (Lewis et al. 
1996, Maul et al. 2003a). 
 
In females, circulating NO is increased 
during follicle development and 
decreased immediately after ovulation 
(Agarwal et al. 2005). In rats, iNOS-
inhibition results in a 50% reduction of 
ovulation, an effect completely reversed 
by NO (Maul et al, 2003a). Endothelial 
NOS knock-out mice exhibit reduced 
hCG-induced ovulation (Maul et al. 
2003a). Data regarding the length of the 
cycle are controversial: whereas Drazen 
et al. (1999) found mice with eNOS 
deletions to exhibit shorter estrous cycles, 
Jablonka-Shariff et al. (1999) observed 
longer estrous cycles in eNOS knock-out 
mice compared with controls. In this 
regard iNOS may be without effect, 
because the lack of iNOS did not alter the 
cycle length (Jablonka-Shariff et al. 
1999). Neuronal NOS knock-out mice 
also seem not to be different from wild-
type mice regarding ovulation or cycle 
length, suggesting nNOS not to be of 
Mervi Väisänen-Tommiska
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importance in this process (Jablonka-
Shariff and Olson 1998). 
 
Both the constitutive and the inducible 
NOSs are present in human tubal cells 
(Rosselli et al. 1996, Ekerhövd et al. 
1997, Agarwal et al. 2005). Nitric oxide 
relaxes smooth muscles (Agarwal et al. 
2005). Deficiency of NO may lead to tubal 
motility dysfunction, resulting in retention 
of the ovum, delayed sperm transport and 
infertility (Agarwal et al. 2005). 
Furthermore, increased NO levels in the 
Fallopian tubes are cytotoxic to invading 
microbes (Rosselli et al. 1995, Rosselli 
1997). Thus, NO may protect against 
ascending pelvic infection. High tubal NO 
release may also be toxic to spermatozoa 
(Rosselli et al. 1995, Rosselli 1997). 
 
Nitric oxide regulates endometrial 
functions such as endometrial receptivity, 
implantation and menstruation (Shi et al. 
2003, Sun et al. 2003, Mörlin and 
Hammarström 2005). It mediates spiral 
arterial changes in decidualization (Maul 
et al. 2003a), and promotes embryo 
implantation (Zhang et al. 2005). In 
guinea pigs and baboons NO may 
account for the vasodilatation during the 
initial stages of trophoblast migration 
(Maul et al. 2003a). 
 
In addition to the above, NO production is 
essential for maintaining pregnancy. In 
early preimplantation embryonic 
development NO regulates mitotic 
division (Tranguch et al. 2003). Placental 
perfusion is also controlled in part by NO 
(Maul et al. 2003a). Fetal membranes are 
rich in NO, and oxytocin stimulates NO 
release in fetal membranes at term 
(Ticconi et al. 2004). 
 
Endothelial dysfunction is important in the 
pathophysiology of preeclampsia (Ranta 
et al. 1999, Jokimaa et al. 2000, Maul et 
al. 2003a). Endothelial function changes 
before the clinical development of 
preeclampsia (Khan et al. 2005). Recent 
studies have revealed NOS gene 
polymorphisms in women at risk of 
preeclampsia (Akbar et al. 2005, Biondi et 
al. 2005, GOPEC Consortium 2005, 
Schiessl et al. 2005), which implies a 
primary role of NO deficiency in this 
condition. 
 
 
 
Figure 2: Nitric oxide controls reproduction. 
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In myometrial tissue all three NOS 
isoforms have been found in various 
species, including humans (Buhimschi et 
al. 1996, Ali et al. 1997, Ekerhövd et al. 
1999). Nitric oxide inhibits uterine 
contractility during pregnancy (Maul et al. 
2003a, Maul et al. 2003b) via activation of 
the soluble guanylate cyclase-cGMP 
pathway, but NO-induced relaxation is 
independent of cGMP (Buxton et al. 
2001, Hoffmann et al. 2003, Tichenor et 
al. 2003). The decreased production of 
NO, as well as the decreased sensitivity 
to NO close to term, may promote the 
initiation of labor (Hertelendy and Zakar 
2004, Okawa et al. 2004a, Okawa et al. 
2004b) (Figure 3). Various NO donors 
inhibit myometrial contractility in 
nonpregnant women and pregnant 
laboring and non-laboring women 
(Norman et al. 1997, Ekerhövd et al. 
1999, Longo et al. 2003), probably by 
mimicking the action of NO. Furthermore, 
transdermal NO donors decrease the 
uterine pulsatility index and resistance 
index (Cacciatore et al. 1998). In fact, NO 
produced by the trophoblast and placenta 
plays a significant role in maintaining 
uterine quiescence and blood flow 
(Cacciatore et al. 1998, Al-Hijji et al. 
2003). 
 
In conclusion, NO appears to be a key 
element in reproduction and pregnancy. 
 
 
 
Figure 3: Changes in the myometrium, cervix and fetal membranes during pregnancy. In the 
myometrium the preparation phase involves changes in transduction mechanisms, in the synthesis of 
calcium ion channels and receptors for uterotonins. At the same time, downregulation of the 
myometrial nitric oxide (NO) system leads to withdrawal of uterine relaxation. 
 
ECM: extracellular matrix. 
 
Contractions
↑ Ca2+ channels
↑ Uterotonin
receptors
↓ NO release
↑ Inflammatory
response
↑ Collagenolysis
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metrium
↑ Ripening DilatationCervix
↑ ECM
degradation
↓ Tissue
integrity RuptureFetal
membranes
Labor
37 weeks to term
25 weeks to term
25 weeks to term
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2. CERVICAL RIPENING 
The human cervix consists of smooth 
muscle cells (10–15%) and connective 
tissue (85–90%) (Danforth 1983) (Figure 
4). The columnar epithelium lining of the 
endocervical canal contains large 
branched glands (Danforth 1983). The 
underlying stroma consists predominantly 
of extracellular connective tissue, mainly 
type I and III collagen bundles (Leppert 
1995, Kelly 2002). In addition, type IV 
collagen is present in smooth muscle 
cells and blood vessel walls (Minamoto et 
al. 1987). Collagen bundles provide a 
rigidity that can be removed rapidly by 
collagenases; the source and control of 
collagenases are not yet fully understood 
(Kelly 2002). 
 
The matrix consists of water, 
glycosaminoglycans and proteoglycans 
as well as dermatane sulfate, hyaluronic 
acid and heparin sulfate (Leppert 1995). 
Elastic fibers with functional elastin are 
located between the bundles of collagen 
fibers in a thin band under the epithelium. 
The ratio of elastin to collagen is highest 
in the area of the internal os (Leppert 
1995). 
 
The cervix undergoes changes in two 
phases: ripening, which involves collagen 
realignment, and dilation (Figure 3). 
Cervical ripening is an integral part of the 
conditioning phase of parturition, and it 
occurs independently of uterine 
contractions (Leppert 1995, Chwalisz and 
Garfield 1998) (Figure 3). Cervical 
ripening resembles an inflammatory 
reaction, which involves a complex 
cascade of degradative enzymes 
accompanied by rearrangement of 
extracellular matrix (ECM) proteins and 
glycoproteins (Leppert 1995, Leppert 
1998, Maul et al. 2003a, Sennström et al. 
2003). The physiologic changes occurring 
in gestation involve hyperplasia and 
hypertrophy of cervical fibroblasts and 
smooth muscle cells, along with 
increasing hydration of the tissue 
(Leppert 1995). 
 
 
 
Figure 4. The internal os of the cervix, where ripening starts, lies in close proximity to the fetal 
membranes. The rigidity of the cervix is largely due to collagens; and thus collagenases soften it. 
 
 
 
PG: prostaglandin 
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 2.1 Control 
Cervical ripening is the result of digestion 
of collagen within the cervix and this is 
followed by an increase in water content 
(Leppert 1995). As the cervix effaces, the 
upper part (the internal os) opens and 
becomes indistinguishable from the lower 
segment of the myometrium (Kelly 2002). 
Thus, at the internal os of the cervix the 
ripening is maximal (Figure 4). In cervical 
dilatation during parturition, catabolic 
enzymes lead to collagen degradation 
and changes in collagen architecture, and 
also to degradation of other structural 
matrix proteins (Kelly 2002). Increased 
production of tumor necrosis factor α 
(TNF α) and interleukin (IL)-1β induces a 
rise in the expression of endothelial 
adhesion molecules, and neutrophils 
extravasating into the cervical stroma 
(Winkler and Rath 1999). Rising 
concentrations of hyaluronic acid have 
been considered as potent inducers of IL-
1 β and TNF- α (Winkler and Rath 1999). 
 
Parturition is associated with an increase 
in IL-1β and IL-6 mRNA expression in the 
cervix, IL-6 and IL-8 mRNA expression in 
the chorio-decidua and IL-1β and IL-8 
mRNA expression in the amnion (Osman 
et al. 2003, Sennström et al. 2000). 
Interleukin-8 is localized in stromal cells, 
macrophages and granulocytes of the 
human cervix (Osman et al. 2003, 
Sakamoto et al. 2004). Levels of cervical 
IL-8 correlate with the release of 
collagenases, which then regulate the 
remodeling of cervical ECM (Garcia-
Velasco and Arici 1999). Cervical IL-8 
levels increase at term vaginal delivery 
(Osman et al. 2003, Sennström et al. 
1997) and correlate with cervical opening 
and with cervical matrix metalloprotease-
8 (MMP-8) content (Osmers et al. 1995a, 
Osmers et al. 1995b). Recently, no 
correlation was found between IL-8 and 
cervical ripening, but IL-8 was involved in 
cervical dilatation (Sakamoto et al. 2004). 
Nevertheless, interleukin-8 has been be 
utilized pharmacologically to ripen animal 
cervix (Kelly et al. 1992, Chwalisz et al. 
1994). 
 
The increase in IL synthesis stimulates 
PG and leukotriene production, causing 
dilatation of cervical vessels and further 
promoting the extravasation of leukocytes 
(Winkler and Rath 1999). The presence 
of activated and degranulated 
polymorphonuclear granulocytes is 
accompanied by degradation of the ECM 
(Leppert 1995). The proteases released 
after degranulation of neutrophils 
encounter an already destabilized 
collagenous fiber network (Winkler and 
Rath 1999). Since the action of proteases 
may lead to severe tissue damage, this is 
strictly limited in time and is controlled by 
increasing concentrations of tissue 
inhibitors of protease (Winkler and Rath 
1999). 
 
Matrix metalloprotease-8 seems to 
correlate most closely to cervical ripening 
and it is localized primarily in the stromal 
tissue (Sennström et al. 2003, Aronsson 
et al. 2005). Matrix metalloproteases -1 
and -3 may also be involved (Sennström 
et al. 2003), although their inhibitors 
resulted in no change in cervical ripening 
induced by misoprostol (Aronsson et al. 
2005). 
 
Progesterone seems to be involved in the 
control of cervical ripening (Figure 5), and 
all antiprogestins studied so far are 
effective agents in inducing cervical 
ripening in all species investigated to 
date, including humans (Garfield et al. 
1998, Neilson 2004). However, the 
mechanism of progesterone action has 
remained poorly understood in women. 
Serum progesterone levels decrease in 
miscarriages (Schindler 2005a), but not 
before term parturition (Schindler 2005a). 
Nevertheless, treatment with an 
antiprogestin is successful for labor 
induction at term (Neilson 2004). The 
human progesterone receptor (PR) exists 
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in two isoforms (PR-A and PR-B), 
mediating different biological responses. 
Functional progesterone withdrawal may 
take place in many ways (Figure 5), i.e. a 
change in PR receptor affinity, PR 
concentration, or a post-receptor effect 
may occur in the myometrium and/or 
cervix. In fact, there is preliminary data 
supporting the hypothesis that 
progesterone withdrawal may take place 
in human myometrium via changes in the 
expression of PR coactivators (Condon et 
al. 2003) or via differential expression of 
PR isoforms (Madsen et al. 2004). 
Interestingly, a recent study showed a 
change in PR isoforms in cervical 
biopsies of women before and after term 
labor (Stjernholm-Vladic et al. 2004b) 
supporting the idea that progesterone 
withdrawal occurs at the receptor level in 
the cervix at parturition. 
 
Cervical ripening involves a wide range of 
inflammatory mediators, including PGs 
and IL-8 (Leppert 1995, Kelly 2002) 
(Figure 5). Uterotonins, like oxytocin and 
endothelin-1, are progesterone-
independent. One such mediator is 
secretory leukocyte protease inhibitor 
(SLPI), which is present in cervical mucus 
(Denison et al. 1999). It is a potent 
inhibitor of neutrophil function (Sallenave 
et al. 1997) and thus opposes the action 
of IL-8, perhaps also in cervical ripening. 
In addition, platelet-activating factor 
(PAF), which is a proinflammatory 
cytokine, accelerates collagenolysis via 
induction of monocyte chemoattractant 
protein 1 (MCP 1) and regulated upon 
activation, normal T cell expressed and 
secreted (RANTES) during cervical 
ripening (Sugano et al. 2001). Finally, a 
number of neuropeptides, such as 
substance P, capsaicin, neurokinin A, 
calcitonin-gene-related peptide, and 
secretoneurin, belong to the substances 
that may contribute to cervical ripening 
(Collins et al. 2002). 
 
Figure 5. Effects of progesterone on the myometrium and cervix during pregnancy and parturition. 
OT: oxytocin; PG: prostaglandin. 
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Although an impressive number of 
molecules have been identified as factors 
involved in cervical ripening, the question 
remains of how they work together to 
enable the process, and whether NO may 
have a role in this phenomenon. 
2.2 Assessment 
Cervical status can predict the success of 
induction and duration of labor (Jackson 
and Regan 1997). Cervical assessment 
has progressed from qualitative (soft or 
firm, ripe or unripe) to quantitative, 
numerically based classifications that 
provide more information. However, no 
objective method for assessing cervical 
ripeness exists (Fuentes and Williams 
1995, Jackson and Regan 1997). 
 
Bishop scoring is based on five factors 
easily evaluated during pelvic 
examination: cervical dilation (cm), 
effacement (%) or length (cm), station, 
consistency (firm, medium, soft) and 
position (posterior, middle, anterior) 
(Bishop 1964). The Bishop score is still 
widely used although it is poorly 
reproducible and suffers from large inter- 
and intra-observer variation (Fuentes and 
Williams 1995, Laube 1997). 
 
Fetal fibronectin (fFN) is a high-
molecular-weight glycoprotein produced 
by the trophoblast and other fetal tissues 
which functions in the maintenance of the 
chorionic-decidual ECM interface 
(Feinberg et al. 1991). It is also present in 
human cervicovaginal fluid (Sennström et 
al. 1998). In the first half of pregnancy, 
fFN normally occurs in cervicovaginal 
fluid (Feinberg et al. 1991), but not after 
the 20th week of gestation (Sibille et 
al.1986). A high level of fFN in the 
cervical fluid may predict preterm birth 
(Ascarelli and Morrison 1997, Goepfert et 
al. 2000). In fact, a cervicovaginal fFN 
value of ≥ 50 ng/mL has been used to 
define women at risk of preterm labor 
(Goepfert et al. 2000). The assessment of 
fFN is confounded by its presence in 
amniotic fluid and in sperm (Lockwood et 
al. 1991, Aumuller and Riva 1992). In 
addition, the measurement of fFN gives 
false results when the sample is bloody 
(Ascarelli and Morrison 1997). Therefore, 
the usefulness of fFN is still limited in 
prediction of the risk of preterm birth. 
 
Insulin-like growth factor-binding protein-1 
(IGFBP-1) is synthesized and secreted by 
the fetal and adult liver, and it is a major 
product of maternal decidualized 
endometrium (Rutanen et al. 1986, 
Julkunen et al. 1988). Different 
phosphoisoforms of IGFBP-1 can be 
identified in cervical fluid by use of 
monoclonal antibodies (Rutanen 2000). 
The detection of amniotic fluid originating 
nonphosphorylated and less 
phosphorylated isoforms of IGFBP-1 in 
cervical samples is diagnostic of the 
rupture of fetal membranes (Rutanen et 
al. 1993, Rutanen et al. 1996). In women 
with intact fetal membranes, detection of 
the highly phosphorylated isoform may 
reflect cervical ripening at term (Nuutila et 
al. 1999) and predict the risk of preterm 
birth (Kekki et al. 2001). 
 
The markers mentioned above are 
clinically used, but have limitations. 
Therefore, there is a strong need for a 
more reliable biological marker which 
could be used in clinics for the 
assessment of cervical ripening or for the 
prediction of the risk of preterm birth. 
2.3 Induction 
Labor induction is routinely used in 
modern obstetrics. In Finland the rate of 
induced labor rose from 13% of live births 
in 1993 to 17% in 2003 (Finnish Birth 
Register 2005). The optimal drug for 
inducing labor should be efficient but not 
cause uterine hyperactivity or have other 
side effects. 
Misoprostol 
Misoprostol, a PG E1 analogue, is 
routinely used for cervical ripening before 
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termination of early pregnancy and for 
induction of labor (Song 2000, Goldberg 
et al. 2001, Goldberg et al. 2003, Alfirevic 
2004, Lin et al. 2005). Misoprostol, 
administered either orally or 
intravaginally, shortens induction-to-
delivery intervals, and lowers the oxytocin 
doses needed during labor (Song 2000, 
Goldberg et al. 2001, Goldberg et al. 
2003, Alfirevic 2004,). In addition, the use 
of misoprostol for labor induction has 
reduced the rate of cesarean section (CS) 
when compared with previously used 
PGs (such as dinoprost) (Sanchez-
Ramos and Kaunitz 2000). Although 
misoprostol can be administered orally, 
rectally or buccally, the vaginal route of 
administration is favored in clinical routine 
owing to its superior clinical efficacy, and 
lack of gastrointestinal side effects 
(Goldberg et al. 2001, Goldberg et al. 
2003). This may be the result of more 
stable plasma levels of the drug after 
vaginal application compared with oral 
administration (Zieman et al. 1997, 
Danielsson et al. 1999, Tang et al. 2002). 
After vaginal application, misoprostol 
reaches its peak plasma level in 80 
minutes (Zieman et al. 1997), but these 
levels show great inter-individual variation 
(Danielsson et al. 1999, Tang et al. 
2002). 
 
Vaginal administration of misoprostol 
carries a risk of uterine hyperstimulation 
in 5–30% of women (Hofmeyr and 
Gulmezoglu 2004, Ramsey et al. 2005). 
Therefore, in many countries misoprostol 
is not used in women with previous CS 
because it may cause rupture of the 
uterine scar (Dodd and Crowther 2004). 
 
The sensitivity of the cervix to misoprostol 
becomes enhanced during pregnancy, 
and, therefore, smaller doses of 
misoprostol (around 25–50 µg per 4 
hours) are needed in late pregnancy than 
in early pregnancy (around 400–800 µg 
per 4 hours) (Goldberg et al. 2001, 
Goldberg et al. 2003). The sensitivity is 
further enhanced in early nonviable 
pregnancy (Barnhart et al. 2004). The 
cause of this phenomenon is unknown. 
 
Misoprostol may stimulate MMP activity, 
either directly or indirectly. It directly 
increases the activity of MMP-1 (Yoshida 
et al. 2002), MMP-8 and -9 
(Shankavaram et al. 1998, Aronsson et 
al. 2005). The indirect effect of 
misoprostol on MMPs could be mediated 
via vasodilatation and influx of leukocytes 
rich in MMPs and cytokines into the 
cervix (Denison et al. 1999, Ledingham et 
al. 1999a, Denison et al. 2000). 
 
Although PGs and NO may act in concert 
in many physiological events, the effect of 
misoprostol on cervical NO release has 
not been studied. 
Mifepristone 
Mifepristone is a PR antagonist used in 
termination of early or mid-pregnancy and 
in inducing labor in late pregnancy 
(Neilson 2004). In nonpregnant women it 
fails to ripen the cervix (Ben-Chetrit et al. 
2004). Beside its antiprogestin effect, it 
also has anti-glucocorticoid and estrogen-
related properties (Olive 2002). 
 
Following oral ingestion, mifepristone is 
rapidly absorbed and the time to peak 
plasma levels is approximately 1–2 h 
(Heikinheimo et al. 1986). It may have 
side effects, such as nausea and vomiting 
(Neilson 2004). 
 
Mifepristone induces uterine contractions 
and bleeding by blocking PRs (Olive 
2002) and by inducing cyclooxygenase 
(COX) activity (Hapangama et al. 2002), 
whereas it is less clear how it brings 
about cervical ripening. Mifepristone 
administration causes an influx of 
leukocytes, specifically neutrophils and 
monocytes, and an increase in MMPs -1, 
-8 and -9 in human cervix (Denison et al. 
2000). In rat cervix the antiprogestin 
onapristone markedly suppressed both 
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cellular proliferation and apoptotic cell 
death (Leppert 1998). 
 
Onapristone has been reported to cause 
a 2.5-fold increase of iNOS mRNA in rat 
cervix (Ali et al. 1997). The effect of 
mifepristone on human cervical NO 
release is unknown. 
2.4 Nitric oxide 
All three isoforms of NOS (nNOS, iNOS 
and eNOS) are present in the human 
uterine cervix (Tschugguel et al. 1999, 
Ledingham et al. 2000, Bao et al. 2001): 
Neuronal NOS is localized in the stroma 
and in epithelial cells (Bao et al. 2001), 
iNOS in the epithelial cells and stromal 
spindle cells (Tschugguel et al. 1999), 
and eNOS in vascular endothelium 
(Tschugguel et al. 1999). 
 
In human studies, inducible NOS has 
been reported to become stimulated in 
the cervix during vaginal delivery 
(Tschugguel et al. 1999, Ledingham et al. 
2000), although not in all studies 
(Thomson et al. 1997). In addition, data 
are not uniform as regards the changes in 
expression of cervical nNOS and eNOS 
during term vaginal delivery: in some 
studies no change was seen (Tschugguel 
et al. 1999, Ledingham et al. 2000), but in 
the others, cervical nNOS expression 
became stimulated (Bao et al. 2001). 
 
In women the concentration of Nox in 
vaginal secretions has been reported to 
be elevated before preterm birth 
(Nakatsuka et al. 2000). Although the 
source of this Nox is not known, both 
infiltrating inflammatory cells and cells in 
the uterine cervix may be responsible. 
Because NO can activate MMPs 
(Yoshida et al. 2001, Biondi et al. 2005) 
and induce apoptotic cell death (Brune et 
al. 1998, Leppert 1998), overproduction 
of NO may be involved in cervical 
ripening, fragility of membranes, and 
subsequent premature delivery. 
 
In animal studies, NO induced cervical 
ripening (Chwalisz et al. 1997) and 
cervical NO release was elevated during 
labor (Buhimschi et al. 1996). Nitric oxide 
shares with TNF-α a unique ability to 
initiate and to block apoptosis, depending 
on multiple variables that are being 
elucidated (Brune et al. 1998). Therefore, 
NO is both an antiapoptotic and an 
apoptotic substance, which may arrest 
cellular turnover and allow reorganization 
of the collagen (Chwalisz et al. 1997, 
Leppert et al. 2000). Nitric oxide may act 
in concert with PGE2 by inducing local 
vasodilatation and by increasing vascular 
permeability and leukocyte infiltration 
(Ekerhövd et al. 2002). In addition, NO 
may directly regulate the activity or the 
production of MMPs (Maul et al. 2003a), 
although Ledingham et al. (1999b) 
demonstrated that the secretion of MMP-
2 and MMP-9 in cervical fibroblasts was 
not regulated by exogenous NO. If NO 
modulates MMPs, the action of NO both 
in the uterus and cervix may be mediated 
partly by MMPs. 
 
In summary, myometrial NO may 
contribute to uterine quiescence during 
pregnancy. In contrast, animal data imply 
that cervical NO is downregulated during 
pregnancy but becomes upregulated 
when the time of labor approaches. 
However, NO regulation in the uterus and 
cervix is not yet fully understood. 
Nitric oxide donors 
In animals, NO donors have been found 
to ripen the cervix (Chwalisz and Garfield 
1997, Shi et al. 2000). In women, NO 
donors such as isosorbide mononitrate 
(IMN) (Thomson et al. 1998, Nicoll et al. 
2001, Ekerhövd et al. 2003, Li et al. 
2003a, Li et al. 2003b, Eppel et al. 2005), 
sodium nitroprusside (Facchinetti et al. 
2000, Chan et al. 2005), and glyceryl 
trinitrate (Thomson et al. 1998, 
Chanrachakul et al. 2000, Sharma et al. 
2005), administered intravaginally or 
intracervically, ripen the cervix during 
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pregnancy (Table 2). In general, NO 
donors appear to be less effective than 
PGs, at least in viable pregnancies, but in 
nonviable early pregnancy IMN was more 
effective than misoprostol (Arteaga-
Troncoso et al. 2005) (Table 2). Sodium 
nitroprusside ripens the cervix even in 
nonpregnant women (Piccinini et al. 
2003). 
 
Nitric oxide donors are safe and have no 
major side effects on the fetus or mother 
(Cacciatore et al. 1998, Bates et al. 2003, 
Ekerhövd et al. 2003, Kahler et al. 2004). 
When compared with misoprostol, NO 
donors were less effective (Ledingham et 
al. 2001), but did not cause uterine 
hyperstimulation (Nicoll et al. 2001, Maul 
et al. 2003b). Thus, NO donors hold 
promise in cervical ripening in women, 
although additional data are needed 
before they can be routinely used in 
clinics. 
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Table 2. Randomized controlled trials on nitric oxide donors in cervical ripening in pregnant women. 
Reference No. of 
women 
Drug & 
dose 
Compared 
with 
Trim Exposure 
time (hrs) 
Comparison of efficacy 
 
Thomson et al. 
1997 
 
48 
 
IMN 
40mg 
GTN 
0.5mg 
 
Placebo 
 
Placebo 
 
 
I 
 
 
 
3 
 
3 
 
 
IMN>Placebo 
 
GTN=Placebo 
Thomson et al. 
1998 
 
66 IMN 
40mg 
IMN 
80mg 
Gemeprost 
1mg 
Gemeprost 
1mg 
I 3 
 
3 
IMN<Gemeprost 
 
IMN<Gemeprost 
Facchinetti et al. 
2000 
 
36 SNP 
5mg 
SNP 
10mg 
Placebo 
 
Placebo 
I 6 
 
3 
SNP>Placebo 
 
SNP>Placebo 
Ledingham et al. 
2001 
65 IMN 
40mg 
Misoprostol 
0.4mg 
I 2–3 IMN<Misoprostol 
Li et al. 
2003a 
126 IMN 
40mg 
Placebo or 
Misoprostol 
0.4mg 
I 4–6 IMN=Placebo 
IMN<Misoprostol 
Chan et al. 
2005 
200 SNP 
10mg + 
Placebo 
Misoprostol 
0.4mg + 
Placebo 
I 3 SNP<Misoprostol 
Arteaga-
Troncoso et al. 
2005 
60 IMN 
80mg 
Misoprostol 
0.4mg  
I 12 
max 4 
doses 
IMN>Misoprostol 
Li et al. 
2003b 
100 IMN 
40mg 
Placebo II 12 
after 1 
dose Miso 
IMN=Placebo 
Eppel et al. 
2005 
72 IMN 
40mg + 
Gemeprost 
1mg 
Placebo + 
Gemeprost 
1mg 
II 48 
max 3 
doses/d 
IMN>Placebo 
Chanrachakul  
et al. 
2000 
110 GTN 
0.5mg 
Dinoprost 
3mg 
III 6 GTN<Dinoprost 
CS rate 35 vs. 35% 
Nicoll et al. 
2001 
36 IMN 
20mg 
IMN 
40mg 
Vaginal 
exam. 
Vaginal 
exam. 
III 6 
 
6 
IMN=vag. exam. 
CS rate 46 vs. 33% 
IMN=vag. exam. 
CS rate 18 vs. 33% 
Ekerhövd et al. 
2003 
60 IMN 
40mg 
Placebo III 4 IMN>Placebo 
Elective CS all 
Sharma et al. 
2005 
65 GTN 
0.5mg 
GTN 
0.5mg 
Misoprostol 
0.05mg 
Dinoprost 
3mg 
III 6 
 
6 
GTN<Misoprostol 
CS rate 43 vs. 48% 
GTN<Dinoprost 
CS rate 43 vs. 52% 
IMN: isosorbide mononitrate; GTN: glyceryl trinitrate; SNP: sodium nitroprusside; CS: cesarean section; 
Comparison of efficacy: which drug caused more cervical ripening; trim: pregnancy trimester 
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AIMS OF THE STUDY 
The present study was undertaken to evaluate cervical NO release in human cervical 
ripening. For this we developed a novel method of Nox assessment in cervical fluid. 
 
The specific aims were to study cervical NO release 
 
1. in normal pregnancy 
2. in early nonviable pregnancy 
3. in postterm pregnancy 
4. in response to the PG analogue misoprostol given vaginally 
5. in response to the antiprogestin mifepristone given orally 
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SUBJECTS AND METHODS 
1. SUBJECTS 
Altogether, 664 women (638 pregnant 
and 26 nonpregnant) were studied during 
the years 2000–2004 (Table 3). The 
Ethics Committee of the Department of 
Obstetrics and Gynecology approved the 
study protocols, and the subjects gave 
informed consent prior to participation. 
 
 
Table 3. Characteristics of study subjects, and design (mean, n, %, range) 
 
 
Study 
 
 
 
I 
 
II 
 
III 
 
IV 
 
V 
 
Number of women 
 
117 
 
239 
 
208 
 
72 
 
28 
Age (yrs) 30.9 
(18–45) 
29.2 
(18–46) 
31.5 
(18–44) 
32.3 
(20–52) 
30.5 
(20–42) 
Nulliparous  62 (53) 126 (53) 76 (37) 30 (42)  0 (0) 
Nonpregnant 
Pregnant  
11 (9) 
106 (91) 
- 
239 (100) 
- 
208 (100)  
15 (21) 
57 (79) 
- 
28 (100) 
Gestational age 
(weeks) 
  Early 
 
  Late 
 
 
8.8 (6–11) 
  (n=19) 
39.7 (37–42) 
  (n=87) 
 
 
8.6 (5–16) 
 
- 
 
 
- 
 
40.7(36–42) 
 
 
8.8 (7–12) 
  (n=26) 
40.4 (37–42) 
  (n=31 ) 
 
 
9.0 (7–12) 
 
- 
Comparison early vs. late 
non- vs. 
laboring 
nonviable vs. 
viable 
postterm vs. 
term 
early vs. late Nox and 
NOSs 
Intervention cervical 
palpation 
amniotomy 
NO donor 
- - misoprostol mifepristone 
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 2. SAMPLES 
2.1 Cervical fluid samples 
Cervical fluid samples were collected by 
the introduction of a Dacron polyester 
swab into the cervix under visual control. 
The swab, kept in the cervical canal 
precisely 20 seconds, was then flushed in 
1.5 mL of physiological saline solution for 
2 minutes. The saline solution was stored 
frozen (-21 °C) until it was analyzed. 
Macroscopically bloody cervical fluid 
samples were discarded. To assess the 
volume of cervical fluid that had been 
soaked up by the Dacron swabs, we 
weighed eleven swabs before and after 
sample collection; the weight increase 
(0.080 ± 0.006 g [mean ± SD]) 
represented the volume of cervical fluid 
obtained (0.080 ± 0.006 mL). By 
multiplying the Nox levels in saline 
solution by the dilution factor (1.5 mL/0.08 
mL = 18.8), we obtained the Nox 
concentrations in the cervical fluid that 
had been soaked up by the Dacron 
swabs. This dilution factor was used for 
each Nox value in studies I–V. 
2.2 Cervical biopsies 
Cervical tissue specimens were taken 
under general anesthesia using 
Shumaker punch biopsy forceps (Stifle 
Lab., Wooburn Green, Bucks, UK). In 
nonpregnant women, this was done 
before the introduction of a Sairges 
instrument into the cervix in association 
with laparoscopic tubal sterilization. In the 
women with first trimester pregnancy, the 
biopsies were taken before Hegar dilators 
were introduced into the cervix. Then, 
pregnancy was terminated by means of 
vacuum suction. Two cervical specimens 
were taken: one was fixed in formalin and 
embedded in paraffin for 
immunohistochemistry and the other was 
snap-frozen in liquid nitrogen and stored 
at -80 °C for subsequent Western 
blotting. 
 
2.3 Blood samples 
A blood sample was collected at the time 
of cervical sampling from 156 women: 
plasma EDTA samples in 46 women in 
Study I (8 nonpregnant, 15 with viable 
early pregnancy, and 23 in late 
pregnancy) and serum samples in 110 
women in Study II (80 with viable early 
pregnancy and 30 with nonviable early 
pregnancy). 
 
Plasma EDTA samples in Study I were 
used for the assessment of Nox. Since 
some food products (for example red 
meat and some vegetables) are known to 
lead to an increase in plasma 
concentration of nitrate (Jungersten et al. 
1996), these women had kept to a low-
Nox diet for 24 hours before sampling, 
and blood was taken after a 12-hour fast. 
 
Serum samples in Study II were used for 
assay of human chorionic gonadotropin 
(hCG) and progesterone. 
3. MEASUREMENT OF NITRIC 
OXIDE 
Cervical fluid samples (500 µL) were 
treated undiluted straight from 
supernatant (first centrifugation: 2200 x g, 
for 10 min +4 °C). Other samples were 
diluted as follows: plasma 1:4 and 
amniotic fluid 1:4 with aqua, and semen 
1:3 with physiological saline. Nox 
concentrations were measured 
spectrophotometrically. This was done 
after nitrate reduction by incubating 125 
µL of the sample with 5 µL (10 U/mL) 
nitrate reductase (Boehringer Mannheim), 
5 µL (20 mM) NADPH (Boehringer 
Mannheim), 5 µL (1 mM) FAD 
(Boehringer Mannheim), and 50 µL PBS 
for 15 minutes. The remaining NADPH, 
which interferes with the chemical 
detection of nitrite, was removed by 
incubation with 1.25 µL (3.75 mM) lactate 
dehydrogenase (Boehringer Mannheim), 
and 100 µL (15 mM) pyruvate (Sigma 
Chemical Co., St. Louis, MO) for 10 
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minutes. Thereafter, protein in the sample 
was precipitated by adding zinc sulfate 
(Merck, Darmstadt, Germany) (1.67 M in 
H2O; 5%), mixing and centrifuging the 
sample at 2200 x g for 10 minutes. Total 
nitrite was then measured by adding 
Griess reagent to the supernatant. This 
was prepared by mixing equal volumes of 
10% p-aminobenzenesulfoamide (Sigma) 
in 25% phosphoric acid (Riedel-de Haen 
AG, Seelze, Germany) and 1% N-(1-
naphthyl)ethylenediamine dihydrochloride 
(Sigma) immediately before use (Green 
et al. 1982, Orpana et al. 1996). The 
Griess reaction was performed in 
duplicate, and absorbance was read at 
546 nm against sodium nitrate (Merck) 
standards (0, 1.25, 2.5, 5, 12.5, 25, and 
50 µmol/L) prepared in water and 
processed in the same way as the 
samples. An individual blank was 
prepared for every sample, and the 
absorbance obtained from the blank was 
subtracted from that of the sample. The 
detection limits of the assay were 3.8 
µmol/L (cervical fluid) and 1 µmol/L 
(plasma, amniotic fluid and semen). The 
intra- and interassay coefficients of 
variation for cervical fluid Nox were 1.6 
and 2.4% and for plasma Nox 3.2 and 
9.6%, respectively. 
 
4. EXPRESSION AND 
LOCALIZATION OF NITRIC 
OXIDE SYNTHASES 
4.1 Immunohistochemistry 
Paraffin sections (5 µm) were used and a 
standard immunohistochemical technique 
(HRP-linked antibody conjugates method) 
was carried out to visualize eNOS and 
iNOS. After the tissues had been 
dewaxed and rehydrated, an antigen 
retrieval procedure was performed. The 
sections were pre-treated by heating in a 
microwave oven at 700 W in 0.01 M citric 
acid buffer (pH 6.0). Endogenous 
peroxidase activity was blocked by 
incubation with 3% hydrogen peroxide. 
Power Vision +TM poly-HRP IHC 
Detection Kits were used, and a Lab 
Vision Autostainer (Lab Vision Corp., 
Fremont, CA, USA). The polyclonal 
antibodies used for the detection of iNOS 
and eNOS (Neo Marker, Fremont, CA, 
USA) (Table 4) were diluted to a 
concentration of 20 µg/mL (1:50) and 
incubated for 60 minutes at room 
temperature. Positive controls for iNOS 
and eNOS were sections of umbilical 
cord, and negative controls included 
slides incubated without primary antibody. 
After the Lab Vision Autostainer 
procedure, counterstaining was carried 
out for ten seconds with Mayer´s 
hemalum solution (Merck 1.09249). The 
slides were then manually mounted. 
 
 
Table 4. Endothelial and inducible nitric oxide synthase  antibodies for immunohistochemistry 
Antibody Type Immunogen Dilution Pretreatment Source 
eNOS (RB-
1711-P1) 
rabbit 
polyclonal 
Peptide from C-terminal of 
human eNOS 1:50  microwave 
Neo 
Marker 
iNOS (RB-
1605-P1) 
rabbit 
polyclonal 
Peptide from C-terminal of 
mouse macrophage iNOS 1:50 microwave 
Neo 
Marker 
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 Three observers blind to the identity of 
the slides performed all the assessments. 
Staining was evaluated semi-
quantitatively using the following system: 
(0) no staining, (1) weak, (2) moderate, 
and (3) strong staining. 
4.2 Western blotting 
Total protein was extracted from the 
cervical tissue biopsy specimens using 
the TriPure Isolation Reagent method 
according to the manufacturer's 
instructions (Roche Applied Science, IN, 
USA). Protein was quantified using the 
Bio-Rad protein assay method (Bio-Rad 
Laboratories, CA, USA) and 
spectrophotometry at 750 nm. Samples 
containing 25 µg protein were prepared 
with application buffer, separated by 
means of Novex® 3–8% tris-acetate gel 
electrophoresis (NuPageTM) and 
transferred to a PVDF (polyvinylidene 
fluoride) membrane (pore size 450 µm) 
(Immobilon-P, Millipore Corp., Bedford, 
MA, USA) by wet blotting (30 V for 2 h). 
The membranes were blocked in 3% 
bovine albumin (Sigma Chemical Co., St 
Louis, MO, USA) in 0.05% v/v Tween–
Tris-buffered saline (TBS-T) for at least 1 
h prior to antibody application. The 
antibodies and concentrations were: 
iNOS (iNOS/NOS Type II, BD 
Transduction Laboratories, Pharmingen, 
USA) at 1:2000, and eNOS (eNOS/NOS 
Type III, BD Transduction Laboratories, 
Pharmingen, USA) at 1:2000. Lysates of 
IFN /LPS-treated mouse macrophages 
(Transduction Laboratories), and human 
endothelial cells (Transduction 
Laboratories) were used as controls for 
iNOS and eNOS, respectively. 
Immunoreactivity was visualized using 
peroxidase-conjugated secondary 
antibody against the appropriate species 
and stained with 3,3´-diaminobenzidine 
tetrahydrochloride (DAB, Fluka Chemie 
GmbH, Germany). Stained molecular 
weight markers (Bio-Rad and Fermentas) 
were transferred to the PVDF membrane 
and used to identify and characterize the 
molecular weights of the NOS isoforms 
examined. 
5. OTHER MEASUREMENTS 
Serum concentrations of hCG were 
measured by solid phase, two-site 
fluoroimmunometric assay (Auto-
DELFIA® Wallac, Turku, Finland) and 
those of progesterone by coated tube 
radioimmunoassay (Spectria, Orion 
Diagnostica, Espoo, Finland), using 
routine laboratory methods. The intra- 
and interassay coefficients of variation of 
the assays were 3.3% and 3.7% for hCG 
and 2.7% and 3.2% for progesterone, 
respectively. 
6. STATISTICAL ANALYSES 
Categorial data were analyzed by means 
of the Chi-square test and Fisher’s exact 
probability test (Studies I–V), by linear 
regression (Study II), by the Armitage test 
for trend (Studies I–II), and by repeated 
measures ANOVA (Studies IV–V). 
Medians with their 95% confidence 
intervals were used to describe Nox 
levels. Because the Nox values were not 
normally distributed they were analyzed 
by means of non-parametric tests, such 
as the Mann-Whitney U, the Kruskal-
Wallis one-way ANOVA, and rank 
correlation tests. All tests were two-sided 
and processed by using NCSS 2000 
software (NCSS Inc., Kaysville, Utah). 
Values of p < 0.05 were considered 
statistically significant. 
 
The data on hCG and progesterone were 
analyzed as absolute values, and also on 
a relative scale, when hCG and 
progesterone concentrations in the 
nonviable pregnancies were expressed 
as percentages of the mean levels of 
these hormones at the same gestational 
point in the control group (Study II). To 
better describe treatment-induced 
changes in cervical fluid Nox levels, we 
also present the Nox data as percentages 
of pretreatment values (Studies IV-V). 
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RESULTS 
The main data are presented here; details 
are shown in the original publications. 
1. METHODOLOGICAL ASPECTS 
1.1 Nitric oxide metabolites in 
cervical fluid (Study I) 
Because this assessment was novel, we 
studied the possible effects of various 
confounders (Table 5) and assessed the 
levels of possibly interfering sources of 
Nox (Table 5) in Study I. No correlation (r 
= 0.14, p = 0.41) was observed between 
plasma and cervical fluid Nox. Palpation 
of the cervix caused an increase in 
cervical fluid Nox, and rupture of fetal 
membranes was accompanied by a 
decrease (40%) in Nox concentrations 
(Table 5). The cervical application of a 
NO donor was followed by an increase in 
cervical NO release and the baseline Nox 
concentration was reached in 18 minutes. 
Hence, women with ruptured membranes 
were always excluded from our studies, 
and no manual palpation of the cervix 
was allowed for three hours before 
sample collection. 
 
The assay was reproducible as regards 
cervical fluid; when two parallel samples 
were collected simultaneously they 
showed a mean inter-sample difference 
of 11% (n = 16). The detection limit of 
cervical fluid Nox concentration was 3.8 
µmol/L. 
 
The cervical fluid range of Nox 
concentration (from undetectable to 2068 
µmol/L) differed from the ranges in 
plasma, amniotic fluid and semen (Table 
5). 
 
 
 
Table 5. The possible confounders of cervical nitric oxide (NO) release.  
GTN: glyceryl trinitrate, Nitro®  Orion, Espoo, Finland
 
  
Confounder 
 
n 
 
Effect/ 
×-fold 
of initial 
 
p 
 
Nox range 
(µmol/L) 
 
Cervical palpation 
 
11 
 
6.6 
 
0.007 
 
Amniotomy  
Amniotic fluid 
 
7 
11 
0.6 0.3  
14.5–102.1 
Plasma 46   2.0–48.3 
Blood in sample 19 0.6 0.07  
Administration of the 
intracervical NO 
donor GTN 0.5 mg 
 
3 
 
5–300 
 
 
0.02 
 
 
Semen 10   5.6–9.4 
     
Mervi Väisänen-Tommiska
  30
1.2 Expression and localization of 
nitric oxide synthases in the cervix 
(Study V) 
Because we measured NO as its 
metabolites we wanted to confirm that the 
enzymes responsible for NO release are 
present in cervical cells. 
Immunohistochemistry 
iNOS 
Inducible NOS was detected in the 
vascular endothelium, pericytes and 
fibroblasts in women with early viable 
pregnancy. The ratio of iNOS expression 
in the endothelium vs. that in the 
pericytes was low. Cervical iNOS staining 
was considered weak (grade 1) in 5 of the 
6 women and moderate (grade 2) in one 
woman. 
 
eNOS 
Endothelial NOS was present in the 
vascular endothelium, the parabasal cells 
of the surface epithelium and the cervical 
glandular epithelial cells in early 
pregnancy. The endothelium/pericyte 
ratio in staining was high as regards 
eNOS expression. Cervical eNOS 
staining was considered weak (grade 1) 
in 2, moderate (grade 2) in 2, and strong 
(grade 3) in 2 of the 6 women. 
Western blotting 
Western blotting confirmed the presence 
of protein for both of iNOS (130 kDa) and 
eNOS (140 kDA) isoforms in the cervix 
(Figure 6). 
 
 
Figure 6. Examples of the detection of inducible nitric oxide synthase (iNOS) (panel A) and 
endothelial nitric oxide synthase (eNOS) (panel B) by Western blotting in one woman with early viable 
pregnancy and no treatment (No treat), and in one woman pretreated with mifepristone (Mife). 
 
 
  Pos control   No treat            Mife
iNOS 
130 kDa 
eNOS 
140 kDa 
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2. NITRIC OXIDE IN NORMAL 
PREGNANCY (Study I) 
 
Cervical fluid Nox was detectable in 46% 
of the nonpregnant women, in 68% of the 
women in early pregnancy, and in 82% of 
the women in late pregnancy (Figure 7).  
The cervical fluid Nox concentration in 
term pregnancy with a ripe cervix but 
without uterine activity was higher (p < 
0.0001) than that in term pregnancy with 
an unripe cervix (Figure 7). Cervical NO 
release was higher (p = 0.008) in parous 
than in nulliparous women, and it was 
related to the Bishop score (r = 0.39; p = 
0.01). 
 
 
Figure 7: Cervical fluid Nox concentrations and group-specific medians in nonpregnant and pregnant 
(pregn.) women (µmol/L). 
not detectable
Nonpregnant Early pregnancy Late pregn. unripe                        Late pregn. ripe
1000
100
10
1
 
3. NITRIC OXIDE IN EARLY 
NONVIABLE PREGNANCY 
(Study II) 
 
Women with missed abortion or blighted 
ovum more often had detectable and 
higher cervical fluid Nox levels than did 
women with early viable pregnancy 
(Figure 8). In addition, the Nox 
concentration in the missed abortion 
group was significantly higher than that in 
the blighted ovum group (Figure 8). In 
contrast, tubal pregnancy did not induce 
cervical NO release (Figure 8). The 
duration of amenorrhea was not a 
determinant as regards cervical fluid Nox, 
but women with a history of previous 
miscarriage had higher (p = 0.02) Nox 
levels (n = 21, median 73.9 µmol/L, 95% 
CI 52.2–95.1) than women without such a 
history (n = 71, median 20.0 µmol/L, 95% 
CI 12.6–46.4). 
 
Cervical fluid Nox concentrations were 
inversely related to serum progesterone 
levels, but bore no relationship to serum 
hCG levels. 
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The likelihood of experiencing incomplete 
abortion following mifepristone-
misoprostol or expectant management in 
the missed abortion or blighted ovum 
group was higher in women with median 
or lower cervical fluid Nox concentrations 
than in those with Nox levels above the 
group-specific median (Table 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Rate of complete or incomplete 
abortion following a mifepristone-misoprostol 
regimen or expectant management in women 
with nonviable early pregnancies with regard to 
the group-specific median cervical fluid nitric 
oxide metabolite (Nox) level (n; %). 
 
 
Cervical fluid Nox 
 
Variable 
≤ median  >median
 
p 
 
Nonviable 
pregnancy 
 
 
25 
 
25 
 
 
• Complete  18 (72%) 24 (96%) 0.12
• Incomplete 7 (28%) 1 (4%) 0.04
Figure 8: Levels of cervical fluid nitric oxide metabolites (Nox) in women with missed abortion (n = 
56), blighted ovum (n = 36), tubal pregnancy (n = 7) or normal intrauterine pregnancy (n = 140). The 
medians are shown by lines. 
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4. NITRIC OXIDE IN POSTTERM 
PREGNANCY (Study III) 
 
Cervical fluid Nox levels were less often 
detectable and 4.5 times lower in women 
going postterm than in those delivering at 
term (Figure 9). Cervical fluid Nox levels 
were significantly and similarly related to 
Bishop score. However, women with 
postterm pregnancy exhibited a lower 
median cervical fluid Nox concentration 
against one Bishop score; this ratio was 
7.8 in the postterm group compared with 
17.7 in the term group. 
 
The cervical fluid Nox concentration was 
inversely related to the time elapsed from 
sample collection to spontaneous 
initiation of labor and to the duration of 
delivery in women delivering postterm, 
but not in women delivering at term. 
 
In women with postterm pregnancy, a 
cervical fluid Nox level below the median 
concentration (low Nox) was associated 
with a less ripe cervix, lower inducibility of 
labor and a longer duration of labor than 
in women with Nox above the median 
level (high Nox). Women with failed 
progression of labor were 8.1 times more 
likely to belong to the low Nox group than 
to the high Nox group. 
 
 
Figure 9: Cervical fluid nitric oxide metabolite (Nox) concentrations in women going postterm and in 
women delivering spontaneously at term (µmol/L). Medians are shown by lines. The detection limit of 
the assay was 3.8 µmol/L.  
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 5. EFFECT OF MISOPROSTOL 
(Study IV) 
Cervical NO release was induced by 
vaginally administered misoprostol in 
pregnant, but not in nonpregnant women 
(Figure 10). Moreover, relatively similar 
stimulation in early and in late pregnancy 
could be accomplished with very different 
doses: the dose in late pregnancy was 
only 6% of the misoprostol dose 
administered in early pregnancy. This 
effect of misoprostol was specific, since 
placebo had no effect on cervical NO 
release either in early or in late 
pregnancy (Figure 10). 
 
After misoprostol administration in the 
nonpregnant group, the cervix was 
softened in 29% of nulliparous women 
and in 38% of parous women. In the early 
pregnancy group this happened in 50% of 
nulliparous and in 71% of parous women. 
Use of placebo was associated with a 
softened cervix in 33% of parous women 
in early pregnancy. The baseline levels of 
Nox, and their responses, showed no 
differences between women with 
softened or tight cervixes. However, in 
the early pregnancy group, elevation of 
Nox levels (median or more) tended to 
occur more often (p = 0.09) in women 
with a softened cervix (70%) than in those 
with a tight cervix (29%) (Figure 11). 
In the late pregnancy group, elevation of 
Nox levels following misoprostol was not 
related to changes in Bishop score (p = 
0.33), but the median cervical fluid Nox 
concentration per one Bishop score rose 
4-fold (97.7 vs. 24.3; p = 0.04) after 
misoprostol. 
 
 
Figure 10: Cervical fluid nitric oxide metabolite (Nox) levels in percentages of initial values (mean ± 
SE) at 1, 2 and 3 hours after vaginal administration of misoprostol in nonpregnant women (-□-), in 
women in early pregnancy (-∆-), in women in late pregnancy (-○-), and after placebo in women in early 
or late pregnancy (-◊-). The dose of misoprostol was 400 µg in nonpregnant subjects and in the early 
pregnancy group, and 25 µg in the late pregnancy group. 
     = p < 0.01,      = p < 0.001 in comparison with baseline. 
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Figure 11: Cervical nitric oxide metabolite (Nox) elevations in 3 hours after vaginal misoprostol 
observed during Hegar dilation in 17 women with early pregnancy. Softened cervix = Hegar dilator of 
size 7 introduced into the cervix without force. Tight cervix = Hegar 7 introduction needing force. 
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6. EFFECT OF MIFEPRISTONE 
(Study V) 
The administration of mifepristone in early 
viable pregnancy was followed by 
significant elevation in cervical fluid Nox 
concentrations (7.4- to 17.2-fold rises) in 
1 to 3 hours (Figure 12). 
 
Immunohistochemistry 
iNOS 
All women except one treated with 
mifepristone showed strong (grade 3) 
cervical iNOS staining, as compared with 
none in the control group (83% vs. 0%; p 
= 0.002). Additionally, iNOS was detected 
in the cervical glands. 
 
eNOS 
The localization and the pattern of 
immunostaining of eNOS in mifepristone-
treated women did not differ from that in 
the controls. 
 
 
 
Western blotting 
 
Western blotting confirmed the presence 
of protein for both of iNOS (130 kDa) and 
eNOS (140 kDA) isoforms in the cervix 
(Figure 6). 
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Figure 12: Levels of nitric oxide metabolites (Nox) in cervical fluid (percentages of initial values; mean 
± SD) in women in early pregnancy (-○-) at 1, 2 and 3 hours after administration of mifepristone (200 
mg), and placebo (-□-). 
***  = p < 0.001 in comparison with baseline. The 1-hour response differed significantly (p = 0.02) 
from the 3-hour one in the mifepristone group, and placebo had no effect. 
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DISCUSSION 
Since the discovery that endothelium-
derived relaxing factor was NO (Ignarro et 
al. 1987, Palmer et al. 1987), a large 
body of research has revealed that NO 
acts as a mediator in a variety of 
physiological and pathophysiological 
conditions (Moncada and Higgs 1993, 
Davis et al. 2001, Korhonen et al. 2005). 
Because impaired endothelium-derived 
vasodilatation is related to coronary heart 
disease and atherogenesis (Hambrecht et 
al. 2000), NO is described as the primary 
endothelium-derived anti-atherosclerotic 
factor (Sumi et al. 2001). In addition to its 
vasoregulatory properties, NO exerts 
inhibitory effects on leukocyte adhesion 
and platelet aggregation (Änggård 1994, 
Mayer and Hemmens 1997, Ignarro et al. 
1999, Aktan 2004). Furthermore, NO is 
also involved in inflammation, host 
defense, as well as in reproduction (Maul 
et al. 2003a, Aktan 2004, Korhonen et al. 
2005). 
Feasible assay 
Although NO has been implicated most 
strongly with vascular physiology, a 
plausible possibility existed (Chwalisz and 
Garfield 1997, Chwalisz et al. 1999, Maul 
et al. 2003a) that it could also be involved 
in human cervical ripening. Therefore, we 
developed a method for the assessment 
of NO metabolites (Nox) in cervical fluid, 
a method that employs 
spectrophotometry and Griess reagent 
(Green et al. 1982). This method was 
reproducible and no correlation was 
observed between plasma and cervical 
fluid Nox concentrations. Cervical fluid 
Nox levels were not affected by dietary 
intake in Study I. Although we instructed 
our subjects in Study I to follow a Nox-
free diet before sampling, we were unable 
to confirm if dietary restrictions were 
followed at home. Furthermore, the Nox 
concentration in sperm was only 1 to 10% 
of that in cervical fluid, suggesting that 
sperm, possibly present in cervical fluid, 
is not a major confounder as regards 
assessment of cervical fluid Nox, nor 
does it account for high values assayed. 
In contrast, cervical palpation accelerated 
cervical NO release, as it is known to 
trigger cervical ripening through a number 
of local bioregulators (McColgin et al. 
1993), and therefore no palpation was 
allowed during a three-hour period prior 
to sample collection. Rupture of the 
membranes decreased cervical fluid Nox 
values by 40%. This may be due to the 
flushing effect of amniotic fluid, since Nox 
concentrations in amniotic fluid were only 
10% of the level of cervical Nox. 
Therefore, all women with ruptured 
membranes were excluded. The 
presence of blood in cervical fluid 
resulted in a reduction of Nox levels, 
because hemoglobin binds to NO and 
forms a complex of nitrosylhemoglobin 
(HbNO) (Kankaanranta et al. 1996). That 
is why we carefully excluded all women 
whose cervical fluid samples were visibly 
bloody. Cervicovaginal infections, 
accompanied by a release of cytokines 
and PGs, may stimulate NO production 
(Fang et al. 1999, 2001, Maul et al. 
2003a) and therefore we excluded 
women with any signs of cervicovaginal 
infection. Finally, to confirm the synthesis 
of NO in cervical cells, we assessed the 
concomitant expression of iNOS and 
eNOS by immunohistochemistry and 
Western blotting in early pregnancy, and 
related them to Nox levels. Both these 
methods carry some uncertainties, since 
the used antibodies may cross-react with 
enzymes other than NO synthases, and 
therefore, for further confirmation of the 
presence of iNOS, the polymerase chain 
reaction (PCR) method should be 
employed. Nevertheless, on the whole, 
we are confident that assay of cervical 
fluid Nox is a feasible and reliable method 
for assessing cervical NO release. 
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Stimulatory effect of pregnancy 
Our data show that cervical NO release 
increases during human pregnancy. 
These results are in line with those from 
animal studies (Buhimschi et al. 1996, Ali 
et al. 1997, Chwalisz and Garfield 1998, 
Garfield et al. 1998, Maul et al. 2003a) 
and some observations on humans, 
obtained by methods different from ours 
(Tschugguel et al. 1999, Ledingham et al. 
2000, Bao et al. 2001). The correlation 
between cervical NO release and Bishop 
scores, and the finding that parous 
women have higher cervical fluid Nox 
concentrations than nulliparous women 
are novel, to the best of our knowledge, 
and these data fit well with the hypothesis 
that local NO has a role in cervical 
ripening (Biondi et al. 2005). A recent 
study showed that the iNOS gene was 
downregulated in the cervixes of women 
after term vaginal labor (Huber et al. 
2005). This may imply that during active 
labor iNOS-derived cervical NO release is 
no longer needed, because the primary 
task of cervical iNOS is in cervical 
ripening. 
Nonviable early pregnancy 
Women with failed early intrauterine 
pregnancy showed elevated cervical NO 
release. We do not believe that increased 
cervical NO, although a very reactive 
molecule, is a primary cause of 
miscarriage. Our view is supported by the 
reduced placental expression of iNOS at 
the fetomaternal interface in women with 
spontaneous abortion when compared 
with that in women with early viable 
pregnancy (Marinoni et al. 2004). Our 
findings could have the following 
explanations. First, elevated release of 
NO in the dying fetus, decidua, and/or 
fetal membranes has been found in LPS-
induced abortions in animal experiments 
(Haddad et al. 1995, Ogando et al. 
2003b), but no such human data exist so 
far. However, it appears plausible that 
remnants of the conceptus could have 
released NO excessively, which could 
have leaked, as either NO or Nox, into 
the cervical canal. This hypothesis is 
supported by our findings: cervical fluid 
Nox levels were elevated only in 
intrauterine miscarriages, not in tubal 
ones, and missed abortion, with 
potentially more abundant remnants of 
conception, was characterized by higher 
cervical fluid Nox levels than cases of 
blighted ovum. Second, spontaneous 
abortion is often associated with a local 
inflammatory reaction in the cervix, and 
this may result in the stimulation of NO 
release through PGs or cytokines 
(Sennström et al. 2000, Maul et al. 
2003a). In addition, many other 
hormones, such as inhibins (Reis et al. 
2000, Muttukrishna et al. 2002, Lahiri et 
al. 2003), may be involved in 
spontaneous abortion and may have 
secondarily stimulated cervical NO 
release in our subjects. Third, increased 
cervical NO release may be a specific 
phenomenon in abortion, perhaps 
triggered by a fall in the level of 
progesterone either locally or in the 
serum (Figure 13). 
Postterm pregnancy 
Cervical NO release was deficient in 
postterm pregnancy. We do not know if 
cervical NO deficiency is a primary 
phenomenon, and thus a true contributing 
factor to postterm pregnancy, or whether 
it is a reflection of relative insufficiency of 
PGs, cytokines, MMPs, or some other 
agents which may be primarily involved in 
cervical ripening (Sennström et al. 1997, 
Sennström et al. 2000, Yoshida et al. 
2001, Kelly 2002, Stygar et al. 2002, 
Yoshida et al. 2002, Osman et al. 2003, 
Sennström et al. 2003, Stjernholm-Vladic 
et al. 2004a) and which may stimulate NO 
release. A high progesterone level seems 
to downregulate the synthesis and 
release of cervical NO. As many as 20–
30% of parous women repeatedly carry 
postterm (Olesen et al. 2003). This 
characteristic seems to be genetically 
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determined (Laursen et al. 2004), and 
therefore we speculate that “postterm 
genes” are functionally linked to the 
genes regulating NO synthases. Such 
women might benefit from the 
administration of a vaginal NO donor 
when induction of labor is needed. 
Relationships to prostaglandins 
It is well established that NO and PGs 
operate jointly in many cells (Dong et al. 
1999, Ledingham et al. 1999a, Boiti et al. 
2003, Hausman et al. 2003, Aktan 2004, 
Gookin et al. 2004, Timoshenko et al. 
2004). Nitric oxide may either stimulate or 
inhibit the release of COX-2, and likewise, 
PGs may have a stimulatory or inhibitory 
effect on iNOS, depending on the cell 
type and/or the presence of cofactors 
(Goharkhay et al. 2002, Maul et al. 
2003a, Ogando et al. 2003a, Timoshenko 
et al. 2004). Our data show that 
misoprostol as a PG analogue induces 
NO release in the uterine cervix of 
pregnant women, and furthermore, the 
response of cervical NO release to PG 
becomes enhanced from early to late 
pregnancy. Thus, PG analogues such as 
misoprostol can perhaps initiate a chain 
reaction in the cervix of pregnant women; 
the initial NO stimulation caused by 
misoprostol is followed by endogenous 
release of PGs triggered by NO. As a 
result, NO, PG and COX pathways may 
have a joint action in human cervical 
ripening, as schematically shown in 
Figure 13. 
Reducing effect of progesterone 
The results of numerous animal 
experiments support the view of 
progesterone having opposing effects on 
NO release in the endomyometrium and 
cervix; it upregulates NO release in the 
former, but downregulates it in the latter 
(Buhimschi et al. 1996, Ali et al. 1997, 
Chwalisz and Garfield 1998, Garfield et 
al. 1998, Maul et al. 2003a). Our data 
imply a link between progesterone and 
cervical NO (Figure 13). First, the lower 
the progesterone level the higher the 
detection rate of cervical fluid Nox in 
nonpregnant women. In fact, 93% of 
women in the follicular phase, versus 
46% of women in the luteal phase 
showed detectable cervical fluid Nox. 
Circulating Nox levels are also higher 
during the follicular phase and at the time 
of ovulation than in the luteal phase 
(Ekerhövd et al. 2001). Second, cervical 
NO release was inversely related to 
circulating progesterone concentrations in 
early nonviable pregnancy in our study. 
Women with threatened abortion or 
preterm birth have considerably lower 
levels of circulating progesterone than 
women with normal pregnancy (Gruber 
and Huber 2005). Progesterone 
insufficiency could well have stimulated 
cervical NO release in nonviable 
intrauterine pregnancy, which may be 
needed for ripening of the cervix during 
the course of miscarriage. Third, cervical 
NO responded to the antiprogestin 
mifepristone with a 17-fold increase in 
cervical fluid Nox and with increased 
expression of iNOS in early viable 
pregnancy. Furthermore, mifepristone 
induced the appearance of iNOS in 
cervical glands, which is a novel finding. 
 
The mechanisms behind mifepristone-
induced NO release are not known, but a 
PR-mediated pathway may be involved 
(Stjernholm-Vladic et al. 2004b). Local 
progesterone withdrawal in the cervix 
brought about by mifepristone may lead 
specifically to the stimulation of iNOS. 
Alternatively, the anti-glucocorticoid 
properties of mifepristone, blocking 
glucocorticoid receptors, may stimulate 
iNOS (Alderton et al. 2001). This would fit 
well with data showing that the levels of 
glucocorticoid receptor decrease in the 
human cervix during labor (Stjernholm-
Vladic et al. 2004a). Furthermore, it is 
possible that mifepristone triggers an 
influx of inflammatory cells, such as 
macrophages, neutrophils and 
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monocytes, which are rich in iNOS. 
Moreover, mifepristone upregulates 
various MMPs and/or the secretion of 
cytokines in cervical cells (Denison et al. 
2000, Maul et al. 2003a, Stjernholm-
Vladic et al. 2004a). These mediators 
may either induce or inhibit iNOS 
depending on the availability of various 
cofactors (Denison et al. 2000, Alderton 
et al. 2001). Furthermore, NO may act in 
concert with the COX pathway, especially 
with COX-II (Brune et al. 1998, 
Hapangama et al. 2002, Hausman et al. 
2003, Maul et al. 2003a) (Figure 13). 
Nitric oxide in turn may soften the cervix 
by remodeling the ECM (Maul et al. 
2003a) (Figure 13), where cytokine-
induced NOS is centrally involved 
(Tschugguel et al. 1999, Maul et al. 
2003a), or by inducing apoptosis of 
cervical cells (Brune et al. 1998, Maul et 
al. 2003a). Taken as a whole, our data 
and those of others (Ali et al. 1997, 
Chwalisz and Garfield 1997, Chwalisz et 
al. 1999, Maul et al. 2003a) can be seen 
as good evidence that NO in the cervix, 
and progesterone, are functionally related 
in pregnancy (Figure 13). In fact, 
administration of progesterone is used in 
treatment of threatened abortion or 
preterm birth (Brancazio et al. 2003, da 
Fonseca et al. 2003, Greene 2003, Di 
Renzo et al. 2005, Schindler 2005b). 
Possible clinical applications 
Cervical fluid Nox may perhaps be used 
as a marker of cervical ripeness in clinics. 
Clinicians could benefit from its 
assessment both in early and late 
pregnancy because this test may indicate 
the readiness of the cervical canal for 
misoprostol or mifepristone priming. As 
regards early pregnancy, women with 
nonviable early pregnancy and “high” 
cervical fluid Nox could perhaps be 
treated expectantly, because these 
women might belong to the 50% of such 
women who will bleed and abort 
spontaneously within 2 weeks (Condous 
et al. 2003). If the test result is “low”, 
priming of the cervix with PGs or 
mifepristone can be considered. In 
addition, our data allow us to speculate 
that women with an unripe cervix may 
benefit from treatment with a NO donor. 
These questions should be studied in 
clinical trials. Likewise, as deficient 
cervical NO release was related to failed 
progression of labor, the cervical fluid 
Nox level may perhaps be used to predict 
the likelihood of successful induction of 
labor in postterm pregnancy. In early as 
well as in postterm pregnancy, NO 
donors may hold a promise, but this 
question has not been studied so far. 
 
No reliable biochemical marker for the 
identification of women at risk of preterm 
birth exists. Fetal fibronectin and IGFBP-1 
have been extensively studied as marker 
candidates, but they have poor predictive 
values and there are major confounders 
in sample collection (Ascarelli and 
Morrison 1997, Goepfert et al. 2000, 
Kekki et al. 2001). Transvaginal 
ultrasonography is also insufficient in 
predicting preterm birth (Honest et al. 
2003, Iams 2003). Although we did not 
study women with preterm birth, our data 
suggest that cervical fluid Nox might 
prove to be a feasible marker for this 
condition. An epidemiological study in this 
connection would need a huge number of 
women; the risk of spontaneous preterm 
birth being 2–3% (Perinatal statistics in 
Nordic countries 2004, Boggess 2005). 
Therefore, we should first study women 
who report preterm contractions in order 
to see if this test can differentiate 
between those women who carry to term 
and those who deliver preterm. Some 
preliminary data suggest that this test 
could be useful in such women 
(Facchinetti et al. 2005). Moreover, it 
could be worthwhile studying if cervical 
fluid Nox levels are related to fFN or 
IGFPB-I levels, which are both of some 
value in prediction of preterm birth 
(Ascarelli and Morrison 1997, Goepfert et 
al. 2000, Kekki et al. 2001). A possible 
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correlation between cervical fluid Nox and 
the concentrations of these substances 
may pave the way to more extensive 
clinical studies on the clinical usefulness 
of the cervical fluid Nox test in the 
prediction of preterm birth. 
 
In summary, our data support the concept 
that the NO pathway, alone or jointly with 
PGs and progesterone (Figure 13), is 
involved in human cervical ripening. 
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CONCLUSIONS 
 
On the basis of the present work, the following conclusions can be drawn: 
 
 
1. Cervical NO release as analyzed by cervical fluid Nox levels is related to 
cervical ripening during pregnancy. 
2. Cervical NO release increases in early nonviable intrauterine pregnancy, and 
“low” NO release predicts incomplete abortion after medical or expectant 
management. 
3. Cervical NO release is deficient in postterm pregnancy and this deficiency may 
contribute to failed progression of labor in postterm women. 
4. Cervical NO release is upregulated by misoprostol in pregnant, but not in 
nonpregnant women. The sensitivity of NO release towards misoprostol is 
enhanced from early to late pregnancy. 
5. Cervical NO release is downregulated by progesterone both in pregnant and 
nonpregnant women. Moreover, antiprogestin stimulates cervical NO release in 
early viable pregnancy. 
6. Nitric oxide is suggested to have a role in human cervical ripening. 
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